Celldex Therapeutics, Inc. (Nasdaq:CLDX) will host a conference call before U.S. financial markets open at 8:30 a.m. Eastern Time on Thursday, March 3, 2011, to provide a year-end summary for 2010 and an update on anticipated research and development and business objectives for 2011. The conference call will be webcast live over the Internet and can be accessed by logging on to the Events Calendar under the “News & Events” section of the Celldex Therapeutics website at www.celldextherapeutics.com. The call can also be accessed by dialing 888-713-4218 (within the United States) or 617-213-4870 (outside the United States). The passcode for participants is 68508575.
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in the development, manufacture, and commercialization of targeted immunotherapies that prevent or treat specific forms of cancer, autoimmune disorders, and diseases caused by infectious organisms.
*********
Spectral Capital Corporation (FCCN) is pleased to announce that it has completed satisfactory due diligence and closed its acquisition of a vast gold resource in the Republic of Kazakhstan. FCCN acquired a 65% interest in the gold resource in a region in Kazakhstan which has already yielded significant gold production. Under the terms of the acquisition, FCCN agreed to provide financing for development and extraction of the gold resource in an amount of $200,000,000 USD over a five-year period. Additionally, FCCN agreed to pay a 1% net smelter royalty on gold extracted from the property and to grant warrants to purchase 5,000,000 shares in Spectral at an exercise price of $3.50 per share.
“This massive resource is ready to produce gold in 2011 and has all the permits required by Kazakh authorities”, stated Jenifer Osterwalder, FCCN CEO. “This resource is substantially larger even than our existing Chita region properties and the reports we received in due diligence indicate that extraction costs should be equal to or lower than extraction costs on our Chita properties. This region of Kazakhstan has attracted investment from some of the world’s leading multi-national mining companies. We are committed throughout 2011 to making Spectral into a company with a diversified portfolio of mineral assets in a variety of areas throughout the world’s most productive mining regions.”
Spectral Capital is focused on the acquisition of a significant portfolio of properties for mining activities. In September 2010, FCCN purchased an interest in mineral properties in the Chita region of the Russian Federation. The Kadara and Kaltagay license is located in the Mogochinsky district of the Chita Region, which has several gold mines in production, in the Russian Federation. Spectral owns 47% of the License for prospecting, exploration and production of gold and all other metals. The length of the License runs to 31 August 2031. The size of the License is 186 square kilometers or 18,200 hectares. Development and exploration activities are currently being undertaken. In January 2011, FCCN acquired a 65% interest in a a gold mine in Kazakhstan, in one of the region’s most promising areas for gold extraction. FCCN continues to develop a diversified portfolio of mineral assets in some of the world’s most productive mining regions.
*********
The Hackett Group, Inc. (Nasdaq:HCKT) announced its financial results for the fourth quarter, which ended December 31, 2010. Fourth quarter 2010 revenue was $48.6 million, a 41% increase from the same period in 2009. Pro forma diluted earnings per share were $0.07 for the fourth quarter of 2010, as compared to pro forma diluted net loss per share of ($0.02) for the same period in 2009. Pro forma information is provided to enhance the understanding of the Company’s financial performance and is reconciled to the Company’s GAAP information in the accompanying tables.
The Hackett Group, Inc. operates as a strategic advisory and technology consulting firm primarily in the United States and western Europe. The Hackett Group, Inc. was founded in 1991 and is based in Miami, Florida.
*********
Arena Pharmaceuticals, Inc. (Nasdaq:ARNA) announced the resignation of Robert E. Hoffman, Vice President, Finance and Chief Financial Officer. Mr. Hoffman, who has accepted a new position in the healthcare industry, will remain in his current role at Arena until the reporting of the company’s year-end results and the filing of the Form 10-K for the year ended December 31, 2010. “We thank Robert for his many years of valuable service and contribution to Arena and wish him the best in his future endeavors,” said Jack Lief, Arena’s President and Chief Executive Officer. “Robert has built a strong finance team at Arena, and we are focused on ensuring a smooth transition when he departs next month.”
Arena Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral drugs in the therapeutic areas of cardiovascular, central nervous system, inflammatory, and metabolic diseases.
********************************************************************
Signup for FREE Daily Stock Alerts From CRWEFinance.com/signup
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWEFinance.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEFinance.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://crwefinance.com/disclaimer) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.Crown Equity Holdings Inc. (CRWE.OB) has received five thousand dollars in cash from a third party (Seo Freisin, Inc) for 1 day advertisement services for Spectral Capital Corporation (FCCN.PK)
